Who is sponsoring NCT01562301?

NCT01562301 is sponsored by M.D. Anderson Cancer Center.

What condition does NCT01562301 study?

NCT01562301 studies Chemotherapeutic Agent Toxicity, Lung Cancer.

What drugs are being tested in NCT01562301?

Interventions: Carboplatin, Docetaxel, Anvirzel, Questionnaires.

What is the status of NCT01562301?

NCT01562301 is currently WITHDRAWN.

Last reviewed 2015-06-05 · How we verify

A Phase I Study of the Combination of Carboplatin, Docetaxel, and Increasing Doses of Sublingual Anvirzel (Nerium Oleander) in Advance Non-Small Cell Lung Cancer

NCT01562301 Phase 1 WITHDRAWN

The goal of this clinical research study is to find the highest tolerable dose of Anvirzel (Nerium Oleander) that can be given to lung cancer patients receiving standard therapy with carboplatin and docetaxel. Researchers also want to learn what effect Nerium Oleander may have in combination with carboplatin and docetaxel.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	WITHDRAWN
Start date	2014-06

Conditions

Chemotherapeutic Agent Toxicity
Lung Cancer

Interventions

Carboplatin
Docetaxel
Anvirzel
Questionnaires

Primary outcomes

Maximum Tolerated Dose (MTD) of sublingual (SL) dosing of Anvirzel in combination with chemotherapy — 21 Day Cycle
Pharmacokinetics of carboplatin and docetaxel when administered concurrently with SL Anvirzel — 24 hours
Pharmacokinetic studies evaluate plasma concentrations over a 24 hour period prior to administration of chemotherapy, using high performance liquid chromatographic and electron ion-spray mass spectrometry